Minerva Neurosciences (NERV) Non-cash Items (2014 - 2026)
Minerva Neurosciences (NERV) reported Non-cash Items of $2.6 million for Q1 2026, up 307.93% on a YoY basis from $637620.0 in Q1 2025, and up 104.81% quarter-over-quarter from $1.3 million in Q4 2025.
Minerva Neurosciences (NERV) Non-cash Items (2014 - 2026) Analysis & Trends
Minerva Neurosciences has reported Non-cash Items for 13 years, with the latest figure at $2.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non-cash Items rose 307.93% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (up 307.93% YoY), and the FY2025 full-year result was $869908.0, up 1791.1% from the prior year.
- Non-cash Items for Q1 2026 stood at $2.6 million, up from $1.3 million in the prior quarter.
- The five-year high for Non-cash Items was $2.6 million in Q1 2026, with the low at $17000.0 in Q2 2024.
- Historically, Non-cash Items has averaged $644121.0 across 5 years, with a median of $375847.5 in 2023.
- Annual changes were most pronounced in 2024 — Non-cash Items tumbled 99.16% — and 2025, when it jumped 2660.87%.
- Minerva Neurosciences' Non-cash Items stood at $242319.0 in 2022, then jumped by 207.45% to $745000.0 in 2023, then tumbled by 93.83% to $46000.0 in 2024, then jumped by 2660.87% to $1.3 million in 2025, then jumped by 104.81% to $2.6 million in 2026.
- The last three Non-cash Items figures came in at $2.6 million (Q1 2026), $1.3 million (Q4 2025), and $756743.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.60 Mn |
| Mar 31, 2026 | 2.60 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 756,743.00 |
| Sep 30, 2025 | 756,743.00 |
| Jun 30, 2025 | 69,670.00 |
| Jun 30, 2025 | 69,670.00 |
| Mar 31, 2025 | 637,620.00 |
| Mar 31, 2025 | 637,620.00 |
| Dec 31, 2024 | 46,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | 450,498.00 |
| Mar 31, 2024 | 450,498.00 |
| Dec 31, 2023 | 745,000.00 |
| Dec 31, 2023 | 745,000.00 |
| Sep 30, 2023 | 301,197.00 |
| Sep 30, 2023 | 301,197.00 |